Eculizumab myasthenia gravis regain trial
WebPurpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis … WebThe REGAIN study was a multinational, double-blind, placebo-controlled, randomized trial evaluating the safety and efficacy of eculizumab in patients with rgMG. Patients were required to be seropositive for AChR …
Eculizumab myasthenia gravis regain trial
Did you know?
WebIn addition, in both groups, most patients who were treated with eculizumab for 130 weeks achieved a Myasthenia Gravis Foundation of America post-intervention status of … WebOct 24, 2024 · UNC Neurologist, Dr. James F. Howard, was the lead investigator in the clinical trial that led to FDA approval. Yesterday the U.S. Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. James F. …
WebFeb 28, 2024 · Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response. However, clinical stabilization is often reached at the … WebCitation 39 In the REGAIN trial, eculizumab-treated patients were two times more likely to have achieved minimal manifestation post intervention status ... The Myasthenia gravis Inebilizumab Trial (MINT) study is a randomized placebo-controlled trial of intravenous inebilizumab (300 mg given on Day 1, 15 and 183) in antibody positive (either ...
WebArticle highlights. Eculizumab is an innovative biological drug blocking the human terminal complement protein C5 with promising activity for the treatment of AChR-positive refractory generalized MG, as demonstrated in REGAIN, a phase III randomized clinical trial. WebIn the phase 3 REGAIN trial, patients with anti-AChR antibody positive, ... Efforts are needed to ensure that new therapies for myasthenia gravis, such as eculizumab and efgartigimod, improve the health of patients and families and do not aggravate existing health inequities. Clinical experts and patients highlighted that the high cost of new ...
WebGeneralized myasthenia gravis (gMG) is a chronic, rare autoimmune disorder that is characterized by severe muscle weakness. 1 Autoantibodies to the acetylcholine receptor are present in 73%–88% of patients with …
WebJan 15, 2024 · In 2024, eculizumab became the second FDA-approved medication for AchR-positive generalized myasthenia gravis (gMG) patients based on the successful … chrismalWebApr 7, 2024 · Results. We identified 84 patients with MG, 11 of whom (13%) met criteria for refractory MG. Mean (standard deviation) age was 47 (18) years; 64% of patients with … geoffrey bond obeWebRecent advances in the diagnosis and treatment of acquired myasthenia gravis (MG) are reviewed. Increased awareness about the need for more uniform methods of reporting … chris malachiWebMay 6, 2024 · Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its … geoffrey bolton library opening hoursWebPost-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension [J]． Neurology ， 2024 ， 96 ( 4 )： e610 - e618 . DOI： 10.1212/wnl.0000000000011207 . geoffrey bond obituaryWebREGAIN Study Group 2024, ' Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase … geoffrey bond mdgeoffreyborough